By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices" report to their offering. A biosimilars boom is expected and both biopharma and contract manufacturers want to be positioned to capture a piece of
By a News Reporter-Staff News Editor at Marketing Weekly News Current study results on Digestive System Diseases and Conditions- Inflammatory Bowel Disease have been published. For more information on this research see: Biosimilars in inflammatory bowel disease: A review of post-marketing experience. World Journal of Gastroenterology, 2017; 23: 1
By a News Reporter-Staff News Editor at Marketing Weekly News New research on Skin Diseases and Conditions- Psoriasis is the subject of a report. To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Council c
The Biosimilars Council, a division of the Association for Accessible Medicines, formerly the Generic Pharmaceutical Association, urges the Supreme Court to recognize that biosimilar medicines can generate billions of dollars in patient and health system savings- but only if patients can access them in a timely manner, as Congress directed.
By a News Reporter-Staff News Editor at Drug Week- Amneal Pharmaceuticals LLC has launched alosetron hydrochloride tablets, an AB-rated generic equivalent to Lotronex , in 0.5 mg and 1 mg strengths. The Amneal product is one of only two FDA- approved generic-equivalents for Lotronex currently available. Amneal's generic received FDA approval
US Food and Drug Administration accepted Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta, for filing through the 351 pathway. Biocon Limited touched a high of Rs 1123 per share, up by Rs 28.35 per share or 2.59% on an intraday basis in Friday's trading session, and this comes in succession to US Food and Drug
Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022.. PUNE, INDIA, February 17, 2017/ EINPresswire.com/ Global Biosimilar Industry Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. However, Asia Pacif
By a News Reporter-Staff News Editor at Drug Week Research and Markets has announced the addition of the "Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices" report to their offering. A biosimilars boom is expected and both biopharma and contract manufacturers want to be positioned to capture a piece of the market.
Upcoming AWS Coverage on Mallinckrodt Post-Earnings Results. LONDON, UK/ ACCESSWIRE/ February 17, 2017/ Active Wall St. blog coverage looks at the headline from Mylan N.V as the Company and Biocon Ltd. announced on February 16, 2017 that the US Food and Drug Administration has accepted Mylan's biologics licence application for MYL-1401H a proposed.
We are presently conducting an open label, Phase II clinical trial of proposed therapy for Gorlin Syndrome, and in August 2016 and October 2016, we announced positive interim data from this trial. We have exclusive rights in the U.S. to develop and to commercialize SUBA-Itraconazole Capsules for the treatment of human cancer via oral administration
Mylan Inc of USA and its Indian partner, Biocon Limited of Bengaluru, have got approval from the US Food and Drug Administration for Mylan's biologics licence application for a proposed biosimilar of branded trastuzumab.
By a News Reporter-Staff News Editor at Health& Medicine Week Investigators discuss new findings in Autoimmune Diseases and Conditions- Rheumatoid Arthritis. According to news originating from Seoul, South Korea, by NewsRx correspondents, research stated, "To assess the efficacy and safety of switching from the infliximab reference product to its
To understand the complexities of the regulatory landscape and key therapeutic issues for use of biosimilars to treat moderate to severe psoriasis in Latin America, the International Psoriasis Council convened dermatology experts from Argentina, Brazil, Chile, Colombia and Mexico in October 2015 to review the definition, approval, marketing and fut
Supply of generic drugs for the Consorci Sanitari Integral centers. Major organization: CONSORCI SANITARI INTEGRAL Address: C/ Jacint Verdaguer 90 08970 St. Joan Desp Country: Spain Url: http://contractaciopublica.gencat.cat Tender notice number: 58575-2017 Notice type: Tender Notice Open date: 2017-03-22.
The US Food and Drug Administration has accepted the application of Mylan Inc and Biocon Limited of Bengaluru for proposed. biosimilar pegfilgrastim, which is used for the treatment of cancer patients undergoing chemotherapy. The proposed biosimilar to Neulasta is used for reducing the duration of neutropenia.
The biosimilars market offers many growth opportunities and driving factors as compared to the restraining factors. It is stated by various research scientists that development of biosimilars will drastically reduce the price of the pharmaceutical drugs.Chicago, IL 02/16/2017 The global biosimilars market report offers in-depth analysis of th
Caprion Biosciences Inc. announced today it has presented a poster at the 4 th Biologic Manufacturing Asia, Singapore. Laura McIntosh, Vice-President, Translation Research who added: "We will also be presenting additional results at the 3rd Annual Biologics& Biosimilar Congress in Berlin next March.. Poster presentation at the conference "High Co
In order to ensure an extension of its Ampyra's protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and Mylan as well as ensure it keeps its patents. This is according to Michael Yee, an RBC analyst. Ten companies have been sued
Feb. 16 Healthcare advocates who are pushing for bills to combat rising prescription drug prices in Maryland drew sympathy but also skepticism from state lawmakers Wednesday. We want them to produce generic drugs, "Attorney General Brian Frosh told the Senate Finance Committee. Leana Wen, Baltimore County Executive Kevin Kamenetz, Prince George's
The approval is for ANDA Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution, 5 mg/1. 5 mg per 5 ml, which is a generic version of Hycodan Oral Solution, 5 mg/1. 5 mg per 5 mL, manufactured by Endo Pharmaceuticals, Inc. Lupin, has announced that the Company has received USFDA approval. Lupin Limited is a transnational pharmaceutical
Release date- 15022017- Today Andrew Boyer, Teva's President& CEO of Global Generic Medicines, North America spoke on a panel of industry CEOs during the annual meeting of the Association for Accessible Medicines. The AAM, formerly known as the Generic Pharmaceutical Association, hosted leadership from Teva, Momenta Pharmaceuticals, Lupin Limited a
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Feb. 16, 2017/ PRNewswire/ Mylan N.V. and Biocon Ltd. today announced that the U.S. Food and Drug Administration has accepted Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta , for filing through the 351 pathway. Arun Chandavarkar, CEO and Joint Manag